Table 4.
Summary and statistical analysis of spontaneous activity imaging recordings of 14 day-old networks and T3, K252a, and rapamycin effects.
| T3− | T3+ | T3− × T3+ | Drug × T3 | |||||
|---|---|---|---|---|---|---|---|---|
| Mean ± s.e.m. | n | P# | Mean ± s.e.m. | n | P# | P* | P& | |
| NETWORK FREQUENCY (bursts/min) | ||||||||
| Control | 3.9 ± 0.4 | 10 | 9.6 ± 0.8 | 10 | <0.001 | |||
| K252a | 3.3 ± 0.8 | 5 | 0.501 | 1.6 ± 0.1 | 5 | 0.003 | 0.095 | <0.001 |
| Rapamycin | 4 ± 1 | 5 | 0.426 | 2.5 ± 0.2 | 5 | 0.003 | 0.548 | <0.001 |
| 0.614 | <0.001 | |||||||
| ATTENDANCE (%neurons/event) | ||||||||
| Control | 34 ± 2 | 276 | 42 ± 1 | 576 | <0.001 | |||
| K252a | 70 ± 4 | 83 | <0.001 | 75 ± 5 | 49 | <0.001 | 0.985 | 0.412 |
| Rapamycin | 54 ± 3 | 125 | <0.001 | 38 ± 4 | 115 | 0.005 | 0.037 | <0.001 |
| <0.001 | <0.001 | |||||||
| SINGLE CELL FREQUENCY (bursts/min) | ||||||||
| Control | 1.85 ± 0.05 | 799 | 4.6 ± 0.1 | 880 | <0.001 | |||
| K252a | 2.33 ± 0.02 | 632 | <0.001 | 1.54 ± 0.02 | 449 | <0.001 | <0.001 | <0.001 |
| Rapamycin | 2.47 ± 0.08 | 455 | <0.001 | 1.78 ± 0.06 | 439 | <0.001 | <0.001 | <0.001 |
| <0.001 | <0.001 | |||||||
| MW-RST | MW-RST | 2w-ANOVA | ||||||
| ANOVA | ANOVA | |||||||
P#, P-value of drug treatment groups vs. untreated controls of the same hormone category; P*, P-value of T3+ vs. T3− of the same drug category. P&, P-values of the interaction between T3 and drug effects. The statistical test used is indicated under the P columns. P# and P*-values from Mann–Whitney Rank sum test (MW-RST), except the italic-underlined P-values, which are results of Kruskal–Wallis One-Way ANOVA on ranks (ANOVA). P&, P-values obtained with Two-Way ANOVA. n, number of fields (Network frequency), number of events (Attendance), and number of cells (Single cell frequency) analyzed per condition.